Opinion|Videos|March 15, 2024
Efficacy of Zanubrutinib vs Acalabrutinib in R/R CLL: A Matching-Adjusted Indirect Comparison
A comprehensive discussion on a matching-adjusted indirect comparison study investigating the efficacy of zanubrutinib vs acalabrutinib in relapsed/refractory chronic lymphocytic leukemia.
Advertisement
Advertisement
Related to this article
Jeff Sharman, MD, explores how targeted therapies have transformed CLL treatment and what emerging approaches could shape the future of care.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Anito-Cel Delivers Durable Responses With Low Neurotoxicity in RRMM
2
Risk, Histology, and Metastatic Site Guide First-Line RCC Treatment Choices
3
FDA Application Withdrawn for I-DXd in Small Cell Lung Cancer
4
Elinzanetant Gets Priority Review for VMS From Breast Cancer Endocrine Therapy
5